Egetis Therapeutics AB (publ) (EGTX) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.259x

Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) has a cash flow conversion efficiency ratio of -0.259x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-64.30 Million ≈ $-6.92 Million USD) by net assets (Skr248.70 Million ≈ $26.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EGTX stock market capitalisation for the company's overall valuation and market capitalisation.

Egetis Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Egetis Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Egetis Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Egetis Therapeutics AB (publ) ranked by their cash flow conversion efficiency. Explore Egetis Therapeutics AB (publ) earnings quality ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Zinwell Corporation TW:2485	-0.022x
Shanghai Lianming Machinery Co Ltd SHG:603006	0.006x
Shenzhen Mingdiao Decoration Co Ltd SHE:002830	0.043x
ARTS Group Co Ltd SHG:603017	0.042x
Mangalore Chemicals & Fertilizers Limited NSE:MANGCHEFER	0.255x
Jiangyin Pivot Automotive Products Co. Ltd. SHE:301181	0.011x
Brasilagro Adr NYSE:LND	-0.035x
Lanner Electronics TWO:6245	0.034x

Annual Cash Flow Conversion Efficiency for Egetis Therapeutics AB (publ) (2010–2025)

The table below shows the annual cash flow conversion efficiency of Egetis Therapeutics AB (publ) from 2010 to 2025. View Egetis Therapeutics AB (publ) (EGTX) stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr338.70 Million ≈ $36.45 Million	Skr-267.10 Million ≈ $-28.74 Million	-0.789x	-70.56%
2024-12-31	Skr492.90 Million ≈ $53.04 Million	Skr-227.90 Million ≈ $-24.53 Million	-0.462x	+9.39%
2023-12-31	Skr545.60 Million ≈ $58.72 Million	Skr-278.40 Million ≈ $-29.96 Million	-0.510x	-48.87%
2022-12-31	Skr506.20 Million ≈ $54.48 Million	Skr-173.50 Million ≈ $-18.67 Million	-0.343x	-38.84%
2021-12-31	Skr527.04 Million ≈ $56.72 Million	Skr-130.11 Million ≈ $-14.00 Million	-0.247x	-15.45%
2020-12-31	Skr629.63 Million ≈ $67.76 Million	Skr-134.64 Million ≈ $-14.49 Million	-0.214x	+16.41%
2019-12-31	Skr244.88 Million ≈ $26.35 Million	Skr-62.64 Million ≈ $-6.74 Million	-0.256x	+30.13%
2018-12-31	Skr219.36 Million ≈ $23.61 Million	Skr-80.31 Million ≈ $-8.64 Million	-0.366x	-28.47%
2017-12-31	Skr303.71 Million ≈ $32.68 Million	Skr-86.55 Million ≈ $-9.31 Million	-0.285x	-207.40%
2016-12-31	Skr389.56 Million ≈ $41.92 Million	Skr-36.12 Million ≈ $-3.89 Million	-0.093x	+91.29%
2015-12-31	Skr48.03 Million ≈ $5.17 Million	Skr-51.15 Million ≈ $-5.50 Million	-1.065x	-133.30%
2014-12-31	Skr90.66 Million ≈ $9.76 Million	Skr-41.38 Million ≈ $-4.45 Million	-0.456x	+23.63%
2013-12-31	Skr46.95 Million ≈ $5.05 Million	Skr-28.07 Million ≈ $-3.02 Million	-0.598x	-0.89%
2012-12-31	Skr53.94 Million ≈ $5.80 Million	Skr-31.96 Million ≈ $-3.44 Million	-0.592x	-260.23%
2011-12-31	Skr87.53 Million ≈ $9.42 Million	Skr-14.40 Million ≈ $-1.55 Million	-0.164x	+57.69%
2010-12-31	Skr6.99 Million ≈ $752.22K	Skr-2.72 Million ≈ $-292.41K	-0.389x	--

About Egetis Therapeutics AB (publ)

ST:EGTX Sweden Biotechnology

Market Cap

$395.78 Million

Skr3.68 Billion SEK

Market Cap Rank

#13580 Global

#216 in Sweden

Share Price

Skr7.91

Change (1 day)

-1.12%

52-Week Range

Skr4.32 - Skr8.06

All Time High

Skr57.90